Genetics

International Stem Cell announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.

International Stem Cell (OTCQB:ISCO) announced the completion of its preclinical studies in Traumatic Brain Injury program will position it to commence a Phase II clinical trial in Australia.
As quoted in the press release:

“Often referred to as a silent epidemic, TBI represents a significant unmet medical need with millions affected annually. Based on the results of our proprietary ISC-hpNSC® demonstrated in our Parkinson’s disease clinical trial and in the preclinical studies conducted by the world-renowned academic collaborator, we believe ISC-hpNSC® can be an effective therapy for TBI” remarked Andrey Semechkin, PhD., Co-Chairman and CEO of ISCO.
“We are very impressed by the results of our TBI preclinical studies. Both motor and cognitive functions improved with neural stem cells ISC-hpNSC® transplantation without any safety issues,” commented Russell Kern, PhD., Executive Vice President and Chief Scientific Officer of ISCO.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX18635.40-198.76
TSXV599.61-16.33
DOW30914.46-53.36
S&P 5003830.48-0.91
NASD11332.34+10.10
ASX6629.30+16.70

COMMODITIES

Commodities
Gold1735.84-33.02
Silver19.21-0.01
Copper3.41-0.01
Palladium1930.58+2.58
Platinum853.00-12.00
Oil96.70-2.80
Heating Oil3.37-0.23
Natural Gas5.53+0.01

DOWNLOAD FREE REPORTS

×